This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.


May 27, 2017
A statewide quality initiative database that included over 11,500 pts undergoing surgical AVR (SAVR) who were assessed for outcomes based on pre-TAVR and post-TAVR time periods (divided into early TAVR and commercial TAVR).  SAVR rates increased with each time period, wheres predicted mortality rates decreased, observed mortality was lowest during th
May 27, 2017
Data from the Centers for Medicare and Medicaid Services related to patients aged 65 and older who underwent TAVR during a 2 year period were evaluated, stratified into older (age 90 or greater; 19.3%) and younger cohorts.  Nonagenarians had fewer comorbidities.  Mortality was higher in nonagenarians (8.4% vs 5.9%) as was morbidity (25.4% vs 21.5%). 
May 17, 2017
Using data from the CoreValve US Expanding Use Study, outcomes for patients with end stage renal disease (ESRD) undergoing TAVR were evaluated using an endpoint of all-cause mortality or major stoke at 1 year.  Mortality at 1 year was 30%, and the stroke incidence was 2.1%.  New permanent pacemaker need was 27%.
May 14, 2017
Bicuspid aortic valve (BAV) has been considered a relative contraindication for transcatheter aortic valve implantation (TAVI). Nevertheless, favourable results have been reported from registries and observational reports.
February 13, 2017
The authors report on an echocardiographic sub-study of the NOTION trial, a prospective randomized study which compared outcomes between 120 patients undergoing TAVI and 112 patients undergoing aortic valve replacement (AVR).
December 27, 2016
The authors report on their findings an ongoing Japanese multicentre prospective registry. They evaluate outcomes in 478 patients undergoing transfemoral  TAVI and treated with percutaneous puncture using an expandable sheath, Edwards Sapien XTprosthesis and a Perclose ProGlide system.
November 23, 2016
Valve in valve transcatheter aortic valve implantation (ViV-TAVI) is an alternative to redo surgical aortic valve replacement (SAVR) in inoperable patients and inpatients at high operative risk.
October 31, 2016
This single institution retrospective study evaluated outcomes of valve replacement for degenerated bioprosthetic aortic valves comparing surgical AVR (SAVR) to transcatheter valve-in-valve procedures (TViV).  Patients were matched into 2 groups of 22 according to STS risk scores.   Operative mortality, stroke rate, and 3-year survival were similar b
October 13, 2016
This is the first report of the use of a balloon expandable transcatheter heart valve (Edwards Sapiens 3) for TAVI in chronic aortic regurgitation (AR) involving non-calcified native valves. The authors implanted Edwards Sapiens 3 prostheses in three patients with severe AR deemed inoperable by the heart team.
September 27, 2016
This analysis of PARTNER data evaluated the impact of chronic kidney disease (CKD) on outcomes after TAVR.  Patients were grouped according to GFR as none/mild, moderate, and severe renal disease.  Severe disease was most common among women with diabetes.